Serum mass profile signature as a biomarker of early lung cancer
详细信息 查看全文
- 作者：Piotr Widlaka ; widlak@io.gliwice.pl" class="auth_mail" title="E-mail the corresponding author ; Monika Pietrowskaa ; m_pietrowska@io.gliwice.pl" class="auth_mail" title="E-mail the corresponding author ; Joanna Polanskab ; joanna.polanska@polsl.pl" class="auth_mail" title="E-mail the corresponding author ; Michal Marczykb ; michal.marczyk@polsl.pl" class="auth_mail" title="E-mail the corresponding author ; Malgorzata Ros-Mazurczyka ; malgorzata.ros@io.gliwice.pl" class="auth_mail" title="E-mail the corresponding author ; Rafał Dziadziuszkoc ; rafald@gumed.edu.pl" class="auth_mail" title="E-mail the corresponding author ; Jacek Jassemc ; jjassem@gumed.edu.pl" class="auth_mail" title="E-mail the corresponding author ; Witold Rzymanc ; wrzyman@gumed.edu.pl" class="auth_mail" title="E-mail the corresponding author
- 关键词：Early detection ; Lung cancer screening ; Mass spectrometry ; Proteomics ; Serum biomarkers
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：99
- 期：Complete
- 页码：46-52
- 全文大小：1115 K
文摘
- •
The value of MALDI-based profiling of serum peptidome as a tool for the early detection of lung cancer and enhancement of LD-CT lung cancer screening was investigated.
- •
The analysis revealed several components with abundances discriminating patients with early lung cancer from healthy high-risk smokers, allowing for the development of an effective cancer discriminator.
- •
The mass profile-based signature has insufficient value as an independent marker (NPV of 88% and PPV of 30%, in a validation stage), yet its clinical usefulness in evaluation of indeterminate pulmonary nodules detected incidentally or within CT screening deserves further investigation.